AI & ML Services × Telehealth & Digital Health
AI & ML Services for Telehealth & Digital Health
Healthcare AI development for digital health companies — LLM features with citation grounding, hallucination controls, and PHI-safe inference architecture.
Why this matters
Why telehealth & digital health need ai & ml services built for them.
Every digital health roadmap now has AI on it, but the gap between a ChatGPT demo and a production clinical feature is enormous — and the failure modes in healthcare are not embarrassing, they are dangerous.
Generic AI consultancies do not carry the healthcare instincts: what a hallucinated drug interaction means, why an unsourced clinical claim is unusable, how PHI must move through an inference pipeline.
We build AI features with the guardrails as the architecture: retrieval-grounded generation with citations, confidence thresholds that route low-certainty outputs to humans, and evaluation suites that measure clinical accuracy before and after every change.
AI features built without audit trails become liabilities the moment something goes wrong. Logging what the model saw, said, and which human approved it is the difference between an incident and an indefensible one.
How we approach it
How Synaptis builds ai & ml services for telehealth & digital health.
Our AI builds for digital health start from a constraint most vendors treat as optional: clinical outputs must be groundable. We architect retrieval-first — the model answers from your vetted corpus and cites what it used, rather than freestyling from training data — and we put humans at every consequential decision point. This is the same citation-first architecture philosophy behind AXIFI, our clinical AI platform, applied to your product's domain. Evaluation is continuous, not a launch gate: accuracy, refusal correctness, and citation fidelity are measured on every model or prompt change.
Compliance considerations
What the regulatory picture looks like.
AI in digital health products faces two regulatory fronts at once. On privacy: PHI entering inference pipelines requires BAA coverage from every model provider in the chain, strict controls on logging and caching (prompt logs are PHI logs), and a hard prohibition on patient data training shared models — vendor defaults frequently violate this until configured otherwise. On product regulation: FDA's Clinical Decision Support guidance draws the line between exempt tools and regulated medical device functions largely on whether clinicians can independently review the basis for recommendations — which makes citation transparency a regulatory strategy, not just a UX nicety.
Features that diagnose, triage, or drive treatment decisions need honest assessment against the device framework before launch, not after. The FTC has separately moved against AI health claims that outrun evidence, so marketing language about your AI's capabilities belongs in compliance review too. This is a general overview only; digital health teams should evaluate their AI features with qualified regulatory counsel before launch.
Go deeper.
Capability deep-dive
AI & ML Services
Everything we ship under ai & ml services — outcomes, process, and use cases.
Explore capability →Industry deep-dive
Telehealth & Digital Health
How we work with telehealth & digital health — common builds, compliance posture, and engagement models.
Explore industry →FAQ
Common questions.
How do you stop the model from making things up?
Architecture, not hope: retrieval-grounded generation so answers come from your vetted sources, citations on every clinical claim, confidence thresholds that route uncertain outputs to human review, and evaluation suites that measure hallucination rates continuously. The model that cannot cite its source does not get to answer.
Can we use OpenAI or Anthropic models with PHI?
Through their healthcare-eligible offerings with BAAs in place, yes — with logging, retention, and training-use settings configured correctly, which defaults rarely are. For some workloads, self-hosted open-weight models inside your compliance boundary are the better answer. We choose per use case rather than by ideology.
Will our AI feature be regulated as a medical device?
It depends on what it does and how transparently it does it. FDA's CDS guidance hinges substantially on whether clinicians can independently review the recommendation basis — one reason we build citation-first. We help you assess the feature honestly against the framework early, because discovering a device classification post-launch is a very expensive surprise.
What does an AI audit trail need to capture?
Enough to reconstruct any output: model and prompt versions, retrieved context, the generation itself, confidence signals, and the human action taken on it. When a clinician asks "why did it say this," the answer should be a query, not an investigation.
Where should a digital health company start with AI?
Where the value is provable and the risk is bounded — usually internal-facing: documentation drafting, intake summarization, care-team copilots with human review. Ship that, build the evaluation muscle and the trust, then climb toward patient-facing features with evidence behind you.
Let's scope ai & ml services for your telehealth & digital health operation.
30-minute working session with a Synaptis architect. We'll discuss your specific workflows and map a build plan.